Medication Fact Sheets
|
January 15, 2025

How Evolocumab Helps Lower LDL Cholesterol Safely

Written By
Medically Reviewed by
Dr. Sarah Daglis ND
Updated On
January 23, 2025

Reducing cholesterol to safe levels is now achievable with an injectable option—this is the promise of evolocumab.

High cholesterol is a significant contributor to heart disease and stroke, posing a major health challenge worldwide. 

While statins have been a common choice for managing cholesterol, Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab, are becoming a valuable alternative for individuals requiring additional support to effectively lower low-density lipoprotein cholesterol (LDL-C).

This article examines how evolocumab functions, its key benefits, and its role in reshaping cholesterol management for the future.

[signup]

What is Evolocumab?

Evolocumab helps support healthy cholesterol levels, especially for individuals who may not achieve their goals with standard approaches.

Evolocumab is part of the PCSK9 inhibitor class, a group of monoclonal antibodies that help lower cholesterol by targeting PCSK9, a protein involved in cholesterol regulation.

Evolocumab, which was approved by the U.S. Food and Drug Administration (FDA) in 2015, is widely used to reduce LDL cholesterol. 

Evolocumab supports cholesterol management in patients with familial hypercholesterolemia who already take standard lipid-lowering therapies, such as statins, but have not yet achieved their target levels.

Mechanism of Action

Evolocumab lowers cholesterol by blocking the PCSK9 protein. This protein typically binds to LDL receptors on liver cells, causing their breakdown and reducing the body's ability to clear LDL cholesterol.

By inhibiting PCSK9, evolocumab protects LDL receptors, allowing the liver to remove more LDL cholesterol from the bloodstream. This approach significantly lowers LDL cholesterol levels and reduces the risk of cardiovascular complications.

Benefits and Efficacy of Evolocumab

Evolocumab has clinically demonstrated efficacy in lowering LDL cholesterol, supported by extensive clinical evidence.

  • When combined with standard lipid-lowering therapies, such as statins, evolocumab has been shown to lower LDL cholesterol levels by more than 60%. It has a rapid onset of action and sustained efficacy over time.
  • The FOURIER trial, involving over 27,000 patients with established cardiovascular disease, demonstrated that evolocumab effectively reduced LDL cholesterol to levels as low as 30 mg/dL in many participants.

Administration and Usage

Evolocumab is administered as an injection under the skin. Depending on the dose and the patient's treatment plan, it is usually prescribed to be taken every two weeks or once a month.

The medication is provided in pre-filled syringes or autoinjectors designed for easy self-administration. It is important to store evolocumab in a refrigerator but allow it to reach room temperature before use. 

Evolocumab is usually administered by a healthcare professional who instructs on its proper use. For patients who continue treatment at home, their doctor ensures they are well-trained in preparing and injecting the medication correctly.

Follow your healthcare provider's instructions and consult the product's labeling for detailed information.

Considerations Before Using Evolocumab

Before starting evolocumab, discuss the possible benefits and risks with your physician to ensure it is a safe and appropriate option for you.

Allergy Precautions

Inform your doctor if you have allergies to foods, preservatives, medications, or latex. Some injection devices contain natural rubber, which may trigger allergic reactions in sensitive individuals.

As stated in the FDA-approved labeling, Evolocumab is contraindicated in individuals with a history of hypersensitivity to its components.

Who Should Use Caution?

  • Children: Not recommended for those under 10 with familial hypercholesterolemia or primary hyperlipidemia, as safety and effectiveness have not been established.
  • Older Adults: Generally well tolerated, but elderly patients may be more sensitive to its effects.
  • Breastfeeding: Limited research is available; consult your doctor to weigh potential risks and benefits.

Potential Interactions

Evolocumab may interact with certain medications, foods, alcohol, or tobacco. To prevent possible complications, provide your doctor with a complete list of all prescription and over-the-counter drugs, supplements, and lifestyle habits.

Monitoring and Safety

Regular checkups and blood tests are essential to track cholesterol levels and identify side effects. Seek prompt medical attention for severe allergic reactions, including facial swelling, difficulty breathing, or a skin rash.

By considering these factors, you and your healthcare provider can determine if evolocumab is the right choice for safely and effectively managing your cholesterol.

Potential Side Effects of Evolocumab

Evolocumab is reported to be well-tolerated in clinical studies, but some individuals may experience side effects. Recognizing these effects and knowing when to seek medical attention is important.

Common Side Effects

  • Mild nausea or diarrhea may occur but usually resolves without treatment.
  • Muscle pain can develop in some individuals, though it is typically temporary.
  • Injection site reactions like redness, irritation, or mild discomfort are common and often subside on their own.

Serious Side Effects

  • Allergic reactions, including itching, hives, skin rash, and swelling of the lips, tongue, or face, require immediate medical attention.
  • Signs of high blood sugar, such as frequent urination, increased hunger, excessive thirst, fatigue, or blurry vision, should be reported to a medical provider.
  • Symptoms of infection, including fever, chills, sore throat, persistent cough, or difficulty urinating, should be evaluated by a doctor as soon as possible.

If you experience any of these side effects, contact a healthcare professional promptly. As this is not an exhaustive list, seek medical guidance if you have any concerns.

[signup]

Key Takeaways

  • Evolocumab improves cholesterol management by blocking PCSK9, helping the liver remove more LDL cholesterol. It is particularly beneficial for those who need additional support beyond standard treatments like statins.
  • It provides an additional option for cholesterol management in specific individuals, with a self-injection system and dosing schedules that fit individual needs, ensuring consistent cholesterol control without significant lifestyle disruption.
  • Regular checkups are essential to monitor cholesterol levels, assess treatment effectiveness, and address potential side effects, allergic reactions, or interactions with other medications.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2021). New therapies for primary hyperlipidemia. The Journal of Clinical Endocrinology & Metabolism, 107(5), 1216–1224. https://doi.org/10.1210/clinem/dgab876

Binod Pokhrel, & Levine, S. N. (2019, April 11). PCSK9 inhibitors. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK448100/

Christie, J. (2024, May 17). How to spot the top warning signs of a stroke. Rupa Health. https://www.rupahealth.com/post/how-to-spot-the-top-warning-signs-of-a-stroke

Cleveland Clinic. (2021a, November 11). Familial hypercholesterolemia: Causes and symptoms. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22067-familial-hypercholesterolemia

Cleveland Clinic. (2021b, November 16). Monoclonal antibodies: Definition & how treatment works. Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies

Cleveland Clinic. (2023). Evolocumab injection. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/20106-evolocumab-injection

Cloyd, J. (2023, March 7). An integrative medicine approach to fatigue. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-fatigue

Cloyd, J. (2024a, February 20). Deciphering diarrhea: Top 5 differential diagnoses every healthcare practitioner should consider. Rupa Health. https://www.rupahealth.com/post/deciphering-diarrhea-top-5-differential-diagnoses-every-healthcare-practitioner-should-consider

Cloyd, J. (2024b, March 4). The role of statins in managing high cholesterol: Benefits and side effects. Rupa Health. https://www.rupahealth.com/post/the-role-of-statins-in-managing-high-cholesterol-benefits-and-side-effects

Cloyd, J. (2024c, March 13). The genetic basis of familial hypercholesterolemia and its clinical implications. Rupa Health. https://www.rupahealth.com/post/the-genetic-basis-of-familial-hypercholesterolemia-and-its-clinical-implications

Cloyd, J. (2024d, June 28). High cholesterol: Causes, implications, and effective management strategies. Rupa Health. https://www.rupahealth.com/post/high-cholesterol-causes-implication

Cloyd, J. (2024e, September 13). Your guide to hyperglycemia (high blood sugar): Causes, symptoms, diagnosis, and treatment options. Rupa Health. https://www.rupahealth.com/post/your-guide-to-hyperglycemia-high-blood-sugar-causes-symptoms-diagnosis-and-treatment-options

Daglis, S. (2024, March 12). Emerging Therapies for Lipid Disorders: PCSK9 Inhibitors and Beyond. Rupa Health. https://www.rupahealth.com/post/emerging-therapies-for-lipid-disorders-pcsk9-inhibitors-and-beyond

ERLICH, D. R. (2016). Evolocumab (repatha) for the treatment of hyperlipidemia. American Family Physician, 94(10), 843–846. https://www.aafp.org/pubs/afp/issues/2016/1115/p843.html#afp20161115p843-b6

Fala, L. (2016). Repatha (evolocumab): Second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia. American Health & Drug Benefits, 9(Spec Feature), 136. https://pmc.ncbi.nlm.nih.gov/articles/PMC5013843/

Khakham, C. (2023, April 6). Understanding your risk of cardiovascular disease with functional medicine labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs

Leiter, L. A., Hegele, R. A., Brown, V., Bergeron, J., Mackinnon, E. S., & Mancini, J. (2024). Review of evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease. Reviews in Cardiovascular Medicine, 25(5), 190–190. https://doi.org/10.31083/j.rcm2505190

Mayo Clinic. (n.d.). Evolocumab (subcutaneous route) description and brand names - Mayo Clinic. Www.mayoclinic.org. https://www.mayoclinic.org/drugs-supplements/evolocumab-subcutaneous-route/description/drg-20152627

Mayo Clinic. (2024). Evolocumab (subcutaneous route). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/evolocumab-subcutaneous-route/description/drg-20152627#drug-proper-use

Rupa Health. (n.d.-a). Low-Density lipoprotein cholesterol. Rupa Health. https://www.rupahealth.com/biomarkers/ldl

Rupa Health. (n.d.-b). Total cholesterol. Rupa Health. https://www.rupahealth.com/biomarkers/total-cholesterol-d8055

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., Sever, P. S., & Pedersen, T. R. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713–1722. https://doi.org/10.1056/nejmoa1615664

Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., Xue, A., Scott, R., Wasserman, S. M., & Rocco, M. (2014). Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance. Journal of the American College of Cardiology, 63(23), 2541–2548. https://doi.org/10.1016/j.jacc.2014.03.019

Weinberg, J. L. (2023, September 18). Integrative dermatology approach to urticaria (hives). Rupa Health. https://www.rupahealth.com/post/integrative-dermatology-approach-to-urticaria-hives

Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Medication Fact Sheets
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.